Loading product details…Cargando detalles del producto…Carregando detalhes do produto…

At a glance

AGORESEARCH
Specification
Category
Form
Knowledge source
Research focus
Reconstitution
Storage
COA

What is TR30?

Dual incretin pathway profile for glucose and body-composition research. The LPPEPTIDE knowledge record describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Tirzepatide 30mg is mapped to LPPeptide SKU TR30. Current storefront values use our product data: 30mg x 10 vials /box, $105.00 USD per box. LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials.

Research context

The LPPEPTIDE knowledge record describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Research generally centers on GIP and GLP-1 receptor signaling, glycemic endpoints, appetite signaling, and body-composition models.

Commonly matched with

TR30 is commonly reviewed alongside RT10, RT20, RT30, TR10, Retatrutide. Keep each combination tied to a defined research objective and lot record.

Compliance notice

TR30 is supplied for research use only. It is not for human or veterinary use, not for consumption, and statements on this page are reference context rather than medical claims.

Research

Reference literature focus

The LPPEPTIDE knowledge record describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Research generally centers on GIP and GLP-1 receptor signaling, glycemic endpoints, appetite signaling, and body-composition models.

Study design notes

Use the LPPeptide product knowledge record, current LPPeptide COA, and internal lab SOP to confirm identity, concentration, and endpoints before this material enters a study. The matched LPPeptide reference specification is 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials.

Dosing & Protocol

LPPeptide handling reference

LPPEPTIDE knowledge source: add 3.0 mL sterile water for 10.0 mg/mL. Reference range is once weekly 2.5-15 mg with stepwise adjustment about every 4 weeks. At 10.0 mg/mL, 1 U equals 100 mcg.

LPPEPTIDE preparation pattern: use sterile technique, add diluent slowly down the vial wall, avoid foaming, roll gently until dissolved, label the preparation date, refrigerate at 2-8 deg C, and protect from light.

Preparation

Tirzepatide 30mg ships as Lyophilized powder. Reconstitution note: LPPEPTIDE knowledge source: add 3.0 mL sterile water for 10.0 mg/mL. Reference range is once weekly 2.5-15 mg with stepwise adjustment about every 4 weeks. At 10.0 mg/mL, 1 U equals 100 mcg.. Record the final concentration and preparation date in the study log.

Storage

Lyophilized: -20 deg C in a dry, light-protected sealed vial. Reconstituted: 2-8 deg C, use within about 4 weeks, and do not refreeze the prepared solution.. Follow the most current lot-specific handling record whenever it is available.

Side Effects

Safety observations

Commonly discussed observations include gastrointestinal pathway effects, appetite changes, dehydration risk in models, and limited compatibility data with adjacent compounds.

Contraindications

Do not use TR30 outside qualified research workflows. Review the current SDS, COA, and protocol exclusions before handling.

Interaction review

Avoid unreviewed combinations with other incretin, insulin, glucose-lowering, or gastric-motility pathway studies.

COA & Testing

Certificate of Analysis

Each LPPeptide lot should be confirmed against current batch documentation before shipment or study use. This product page keeps TR30 visible so the SKU can be matched to the active COA.

Current catalog summary

  • SKU: TR30
  • Product: Tirzepatide 30mg
  • Storefront specification: 30mg x 10 vials /box
  • LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials
  • Listed box price: $105.00 USD
  • Reference: LPPeptide product knowledge record

Testing checklist

  • Peptide identity or material identity
  • HPLC purity or assay result where applicable
  • Batch ID and test date
  • Sterility/endotoxin or accessory checks when applicable
  • Residual solvent and handling notes where applicable
About LPPeptide

Direct catalog supply

LPPeptide product pages use our own SKU, package, price, and stock data first. LPPeptide knowledge mapping adds compound education, handling notes, and specification checks while lot-specific editorial content is being prepared.

Lot-specific content

For final release decisions, use the current product record, COA, handling sheet, and research SOP as the highest-priority source for this page.

What is TR30?

Dual incretin pathway profile for glucose and body-composition research. Coze describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Tirzepatide 30mg is mapped to LPPeptide SKU TR30. Current storefront values use our product data: 30mg x 10 vials /box, $105.00 USD per box. LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials.

Research context

Coze describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Research generally centers on GIP and GLP-1 receptor signaling, glycemic endpoints, appetite signaling, and body-composition models.

Commonly matched with

TR30 is commonly reviewed alongside RT10, RT20, RT30, TR10, Retatrutide. Keep each combination tied to a defined research objective and lot record.

Compliance notice

TR30 is supplied for research use only. It is not for human or veterinary use, not for consumption, and statements on this page are reference context rather than medical claims.

Research

Reference literature focus

Coze describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Research generally centers on GIP and GLP-1 receptor signaling, glycemic endpoints, appetite signaling, and body-composition models.

Study design notes

Use the LPPeptide product knowledge record, current LPPeptide COA, and internal lab SOP to confirm identity, concentration, and endpoints before this material enters a study. The matched LPPeptide reference specification is 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials.

Dosing & Protocol

LPPeptide handling reference

Coze source: add 3.0 mL sterile water for 10.0 mg/mL. Reference range is once weekly 2.5-15 mg with stepwise adjustment about every 4 weeks. At 10.0 mg/mL, 1 U equals 100 mcg. Coze preparation pattern: use sterile technique, add diluent slowly down the vial wall, avoid foaming, roll gently until dissolved, label the preparation date, refrigerate at 2-8 deg C, and protect from light.

Preparation

Tirzepatide 30mg ships as Lyophilized powder. Reconstitution note: Coze source: add 3.0 mL sterile water for 10.0 mg/mL. Reference range is once weekly 2.5-15 mg with stepwise adjustment about every 4 weeks. At 10.0 mg/mL, 1 U equals 100 mcg.. Record the final concentration and preparation date in the study log.

Storage

Lyophilized: -20 deg C in a dry, light-protected sealed vial. Reconstituted: 2-8 deg C, use within about 4 weeks, and do not refreeze the prepared solution.. Follow the most current lot-specific handling record whenever it is available.

Side Effects

Safety observations

Commonly discussed observations include gastrointestinal pathway effects, appetite changes, dehydration risk in models, and limited compatibility data with adjacent compounds.

Contraindications

Do not use TR30 outside qualified research workflows. Review the current SDS, COA, and protocol exclusions before handling.

Interaction review

Avoid unreviewed combinations with other incretin, insulin, glucose-lowering, or gastric-motility pathway studies.

COA & Testing

Certificate of Analysis

Each LPPeptide lot should be confirmed against current batch documentation before shipment or study use. This product page keeps TR30 visible so the SKU can be matched to the active COA.

Current catalog summary

- SKU: TR30 - Product: Tirzepatide 30mg - Storefront specification: 30mg x 10 vials /box - LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials - Listed box price: $105.00 USD - Reference: LPPeptide product knowledge record

Testing checklist

- Peptide identity or material identity - HPLC purity or assay result where applicable - Batch ID and test date - Sterility/endotoxin or accessory checks when applicable - Residual solvent and handling notes where applicable

About LPPeptide

Direct catalog supply

LPPeptide product pages use our own SKU, package, price, and stock data first. LPPeptide knowledge mapping adds compound education, handling notes, and specification checks while lot-specific editorial content is being prepared.

Lot-specific content

For final release decisions, use the current product record, COA, handling sheet, and research SOP as the highest-priority source for this page.

What is TR30?

Dual incretin pathway profile for glucose and body-composition research. Coze describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Tirzepatide 30mg is mapped to LPPeptide SKU TR30. Current storefront values use our product data: 30mg x 10 vials /box, $105.00 USD per box. LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials.

Research context

Coze describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Research generally centers on GIP and GLP-1 receptor signaling, glycemic endpoints, appetite signaling, and body-composition models.

Commonly matched with

TR30 is commonly reviewed alongside RT10, RT20, RT30, TR10, Retatrutide. Keep each combination tied to a defined research objective and lot record.

Compliance notice

TR30 is supplied for research use only. It is not for human or veterinary use, not for consumption, and statements on this page are reference context rather than medical claims.

Research

Reference literature focus

Coze describes Tirzepatide as a 39-amino-acid dual GIP and GLP-1 receptor agonist that supports glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite-pathway research. Research generally centers on GIP and GLP-1 receptor signaling, glycemic endpoints, appetite signaling, and body-composition models.

Study design notes

Use the LPPeptide product knowledge record, current LPPeptide COA, and internal lab SOP to confirm identity, concentration, and endpoints before this material enters a study. The matched LPPeptide reference specification is 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials.

Dosing & Protocol

LPPeptide handling reference

Coze source: add 3.0 mL sterile water for 10.0 mg/mL. Reference range is once weekly 2.5-15 mg with stepwise adjustment about every 4 weeks. At 10.0 mg/mL, 1 U equals 100 mcg. Coze preparation pattern: use sterile technique, add diluent slowly down the vial wall, avoid foaming, roll gently until dissolved, label the preparation date, refrigerate at 2-8 deg C, and protect from light.

Preparation

Tirzepatide 30mg ships as Lyophilized powder. Reconstitution note: Coze source: add 3.0 mL sterile water for 10.0 mg/mL. Reference range is once weekly 2.5-15 mg with stepwise adjustment about every 4 weeks. At 10.0 mg/mL, 1 U equals 100 mcg.. Record the final concentration and preparation date in the study log.

Storage

Lyophilized: -20 deg C in a dry, light-protected sealed vial. Reconstituted: 2-8 deg C, use within about 4 weeks, and do not refreeze the prepared solution.. Follow the most current lot-specific handling record whenever it is available.

Side Effects

Safety observations

Commonly discussed observations include gastrointestinal pathway effects, appetite changes, dehydration risk in models, and limited compatibility data with adjacent compounds.

Contraindications

Do not use TR30 outside qualified research workflows. Review the current SDS, COA, and protocol exclusions before handling.

Interaction review

Avoid unreviewed combinations with other incretin, insulin, glucose-lowering, or gastric-motility pathway studies.

COA & Testing

Certificate of Analysis

Each LPPeptide lot should be confirmed against current batch documentation before shipment or study use. This product page keeps TR30 visible so the SKU can be matched to the active COA.

Current catalog summary

- SKU: TR30 - Product: Tirzepatide 30mg - Storefront specification: 30mg x 10 vials /box - LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials / 15mg x 10 vials / 20mg x 10 vials / 30mg x 10 vials / 40mg x 10 vials / 60mg x 10 vials / 100mg x 10 vials - Listed box price: $105.00 USD - Reference: LPPeptide product knowledge record

Testing checklist

- Peptide identity or material identity - HPLC purity or assay result where applicable - Batch ID and test date - Sterility/endotoxin or accessory checks when applicable - Residual solvent and handling notes where applicable

About LPPeptide

Direct catalog supply

LPPeptide product pages use our own SKU, package, price, and stock data first. LPPeptide knowledge mapping adds compound education, handling notes, and specification checks while lot-specific editorial content is being prepared.

Lot-specific content

For final release decisions, use the current product record, COA, handling sheet, and research SOP as the highest-priority source for this page.